QualityStocks.net News – Lev Pharmaceuticals Inc. (LEVP.OB) Granted Authorization to File for European Distribution Rights for Lead Drug Candidate

We would like to highlight Lev Pharmaceuticals Inc. (OTCBB: LEVP). The company is a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. Lev’s lead product candidate, Cinryze™ [C1 inhibitor (human)], is being developed as a replacement therapy for hereditary angioedema (HAE), also known as C1 inhibitor deficiency. Cinryze™ has been granted orphan drug status for the acute and prophylactic treatment of HAE, potentially securing, upon approval, market exclusivity for seven years.

In the company’s recent news,

Lev Pharmaceuticals Inc. announced a letter of agreement with the Sanquin Blood Supply Foundation, which gives Lev the OK to file for European marketing authorization of C1 to treat the life-threatening attacks associated with HAE, such as inflammation of the larynx, abdomen, face, extremities and urogenital tract. Lev also received authorization from the European Medicines Agency (EMEA) to submit an application for C1 for Community Marketing Authorization through the centralized European registration procedure.

An estimated 10,000 people in the United States suffer from HAE. Per the agreement with Sanquin, Lev holds exclusive rights to market and distribute C1 for the treatment of HAE in North America, and is in discussions with Sanquin to expand distribution to certain European countries.

Lev intends to submit its application to the EMEA in the fourth quarter of 2008, though there is no guarantee Lev will win European rights, or that EMEA will approve any application for Community Marketing Authorization filed by Lev.

About QualityStocks

QualityStocks.net, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks.net is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.

To sign up for “The QualityStocks Daily Newsletter” please visit http://www.qualitystocks.net/

Please see disclaimer on QualityStocks.net website: http://Disclaimer.QualityStocks.net 

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.